从突围到引领 18A第一股歌礼制药开启发展2.0时代

e公司
Nov 10

在中国生物科技行业的跌宕起伏中,歌礼制药(1672.HK)的发展轨迹颇具启示意义。从作为港交所18A生物科技第一股的高光上市,到商业化遇挫的低谷徘徊,再到凭借极具差异化的减重管线重获市场认可,这一历程不仅记录了企业的韧性成长,更凸显了创新药企业家卓越的研发洞察力与战略决断力。歌礼制药的转型之路,为中国创新药企的破局突围提供了极具价值的范本。远见卓识:从低谷到价值重估的战略转身2018年8月,歌礼...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10